NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has earned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $6.50.
Several research analysts have recently commented on the stock. Roth Capital lowered shares of NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $5.00 to $4.00 in a research note on Monday, March 26th. HC Wainwright set a $6.00 price target on shares of NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, March 21st. Finally, Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 15th.
Shares of NBY opened at $3.25 on Thursday. NovaBay Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $5.00.
TRADEMARK VIOLATION WARNING: “NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of “Hold” from Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3389655/novabay-pharmaceuticals-inc-nby-receives-consensus-recommendation-of-hold-from-analysts.html.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.